April 1, 2022
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Joint research agreement with the National Cancer Center on rare cancers

TOKYO, Japan, April 1, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio")
today announced that it has entered into a joint research agreement with the National Cancer Centerfor the MASTER KEY Project*, which is a collaborative industry-academia project mainly conductedby the National Cancer Center Hospital. SymBio will work with the National Center Cancer to develop
pharmaceutical products for rare cancers**.
The Company does not expect the information presented herein to have any material impact on its
financial outlook for the fiscal year ending December 2022.

1

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About MASTER KEY Project*
The "MASTER KEY Project" is an industry-academic collaborative project promoting the developmentof genomic medicine in rare cancers. The project is divided into two parts, a registry study and substudy.
In the registry study, National Cancer Center (NCC) aims to characterize rare cancers, including
molecular biological metrics (biomarkers), by accumulating a large database of rare cancer patientsfor whom no collective clinical information has been accumulated so far.
Also, although multiple clinical trials (sub-study) are conducted in this project, patients enrolled inregistry studies can be offered the opportunity to be referred for optimal sub-trials depending on theresults of individual biomarkers.
Sub-studies can be broadly divided into "trials with biomarkers" that use novel agents with specificpotential efficacy for tumors with specific biomarkers, and "trials without biomarkers" that use
agents that are expected to be effective regardless of the biomarker. Secondary trials that areclassified into one of the two types of trials are conducted at the same time.
Individual rare cancers are difficult to conduct collective research due to the small number ofpatients, but NCC expects that this project will be able to efficiently advance research anddevelopment by selecting the optimal new drug according to the biomarker results, regardless of thecancer type.
NCC aims to deliver more new drugs to patients with rare cancers faster through this project.
* https://www.ncc.go.jp/en/information/press_release/20170731/index.html
About Rare cancers**
Rare cancers are cancers with a low incidence (annual incidence <6 per 100,000 people), which makes
it difficult to research and conduct clinical trials due to the limited amount of available clinical data.
**https://www.ncc.go.jp/jp/rcc/about/index.html
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of AmgenJapan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., called
SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Mr. FuminoriYoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to bea leading global specialty biopharmaceutical company dedicated to addressing underserved medicalneeds.

2